iShares Biotechnology ETF (IBB)
- Fund company
- iShares Trust
- Fund net assets
- $9.1B
- Equity lines
- 239
- Holdings as of
- 30 June 2026
- Source
- N-PORT report, SEC →
Weighted score of the companies held
So far, 41% of the fund is scored by Scorvest. The score is published once more than 50% is: the missing companies are being added.
–
- Profitability
- –
- Balance sheet
- –
- Cash generation
- –
- Stability
- –
- Growth
- –
Fund split by score
- Scored 75+ 12%
- Scored 40–74 18%
- Scored below 40 12%
- Not scored yet 59%
Sectors
Countries
Top holdings
| Company | Weight | Score | |
|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | 8.08% | pending | |
| AMGEN INC | 7.83% | 71 | |
| GILEAD SCIENCES, INC. | 6.84% | 79 | |
| REGENERON PHARMACEUTICALS, INC. | 4.91% | 77 | |
| ARGENX SE | 3.76% | 73 | |
| Alnylam Pharmaceuticals, Inc. | 3.12% | pending | |
| Natera, Inc. | 2.89% | 39 | |
| Revolution Medicines, Inc. | 2.78% | 9 | |
| BIOGEN INC. | 2.47% | 71 | |
| ILLUMINA, INC. | 2.07% | 68 | |
The next 40 holdings are visible from the Essential plan. Try free for 7 days → | |||
Computed from the equity lines reported by the fund. Weights are those of the N-PORT report at the date shown. General information, not investment advice.